• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Novo Nordisk A/S Common Stock (NY:NVO)

    38.56 -1.22 (-3.05%)
    Streaming Delayed Price Updated: 2:06 PM EDT, Mar 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 13,718,610
    Open 39.19
    Bid (Size) 38.56 (300)
    Ask (Size) 38.57 (1,700)
    Prev. Close 39.78
    Today's Range 38.18 - 39.22
    52wk Range 35.85 - 82.57
    Shares Outstanding N/A
    Dividend Yield 3.03%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Novo Nordisk Sentiment Shifts as REDEFINE 4 Trial Results Trigger 16% Stock Plunge
    The long-held dominance of Novo Nordisk (NYSE: NVO) in the global obesity market has been dealt a staggering blow following the release of the "worst-case scenario" results from the REDEFINE 4 Phase 3... 
    Via MarketMinute
    Topics Government
    News headline image
    Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal ↗
    Via MarketBeat

    Performance

    YTD
    -26.4%
    -26.4%
    1 Month
    -21.9%
    -21.9%
    3 Month
    -17.5%
    -17.5%
    6 Month
    -29.0%
    -29.0%
    1 Year
    -51.2%
    -51.2%

    More News

    Read More
    News headline image
    Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss ↗
    Via Stocktwits
    News headline image
    2 Healthcare Stocks That Are Too Cheap to Ignore ↗
    Via The Motley Fool
    News headline image
    Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity
    Via Finterra
    Topics Economy Intellectual Property Lawsuit
    News headline image
    Disrupting the Pharmacy: A Deep-Dive into Hims & Hers Health (HIMS) in 2026
    Via Finterra
    Topics Artificial Intelligence Economy
    News headline image
    Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock ↗
    Via Stocktwits
    Topics Intellectual Property Lawsuit
    News headline image
    HIMS Stock Rockets To Best Day Ever After Novo Nordisk Pact — Wall Street Upgrades Roll In As Shorts Lose $546M In One Day ↗
    Via Stocktwits
    Topics Intellectual Property Lawsuit
    News headline image
    Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy? ↗
    Via The Motley Fool
    Topics Lawsuit
    News headline image
    Novo Nordisk Is Slashing Prices for Ozempic and Wegovy. Here's Why That Might End Up Helping the Stock ↗
    Via The Motley Fool
    News headline image
    Hims & Hers Stock Pops 40%: Everything You Need to Know ↗
    Via The Motley Fool
    Topics Lawsuit
    News headline image
    HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy ↗
    Via Stocktwits
    Topics Intellectual Property Lawsuit
    News headline image
    HIMS Stock Could Rally Up To 60% This Week? Fund Manager Says He Wouldn’t Be ‘Surprised’ As Novo Nordisk Patch-Up Buzz Grows ↗
    Via Stocktwits
    Topics Intellectual Property Lawsuit
    News headline image
    Better Weight Loss Stock: Novo Nordisk Vs. Amgen ↗
    Via The Motley Fool
    News headline image
    2 Underrated Weight Loss Stocks to Buy Now ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Can This Next-Gen Obesity Drug Save Novo Nordisk? ↗
    Via The Motley Fool
    News headline image
    Novo Nordisk To Partner With Hims & Hers To Sell Weight-Loss Drugs: Report ↗
    Via Stocktwits
    Topics Initial Public Offering Intellectual Property Lawsuit
    News headline image
    Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market? ↗
    Via The Motley Fool
    News headline image
    Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors ↗
    Via The Motley Fool
    News headline image
    The Compounding Cliff: Hims & Hers Faces Reckoning as FDA and Big Pharma Close GLP-1 Loopholes
    Via MarketMinute
    Topics Economy Intellectual Property Lawsuit
    News headline image
    Novo Nordisk’s Brief Rebound Fizzles: Apple-Style Justin Long Ozempic Ad Draws FDA Warning Again ↗
    Via Stocktwits
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Unexpected Stock Picks and Looking to the Future ↗
    Via The Motley Fool
    News headline image
    Why I'm Not Worried About Novo Nordisk Stock ↗
    Via The Motley Fool
    Topics Intellectual Property

    Frequently Asked Questions

    Is Novo Nordisk A/S Common Stock publicly traded?
    Yes, Novo Nordisk A/S Common Stock is publicly traded.
    What exchange does Novo Nordisk A/S Common Stock trade on?
    Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
    What is the ticker symbol for Novo Nordisk A/S Common Stock?
    The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
    What is the current price of Novo Nordisk A/S Common Stock?
    The current price of Novo Nordisk A/S Common Stock is 38.56
    When was Novo Nordisk A/S Common Stock last traded?
    The last trade of Novo Nordisk A/S Common Stock was at 03/10/26 02:06 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.